This milestone hardware upgrade has greatly consolidated the company's reproductive genetic technology R&D capabilities and platform advantages. Combined with the company's DA500 device, which has already obtained a registration certificate, it has formed a high-low matching sequencing platform that can provide complete solutions for clinical institutions of different sizes. The certification of DA5000 has significantly enhanced the overall competitiveness of the company's products.
The PGT-M test kit independently developed by ecuador telegram data Beikang Medical has successfully completed clinical trials and obtained the NMPA medical device priority approval channel. It is expected to become China's first PGT-M test kit to block the thalassemia gene in 2025. According to public data, the incidence of thalassemia gene carriers in southern my country is 2.5% to 20%, while the incidences in Guangdong and Guangxi provinces are as high as 10% and 20% respectively. PGT-M technology can help these couples carrying pathogenic genes screen for a healthy embryo, which will make more contributions to improving the quality of regional population in my country.